Incidence of drug-induced hypersensitivity syndrome associated with levetiracetam and clobazam is likely underreported
The FDA recently issued a statement requiring manufacturers of levetiracetam and clobazam to include warnings regarding drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) to patients and their caregivers.1 Levetiracetam, an anti-epileptic, is rarely associated with DiHS/DRESS, and clobazam, a benzodiazepine prescribed as an anxiolytic and anti-epileptic, has recently been linked to DiHS/DRESS.2-5 It is estimated that over 12 million prescriptions of levetiracetam and 750,000 prescriptions of clobazam were filled in 2022 in the United States.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Nikhita R. Kichili, Alyssa Hansen, Dheeraj Kagithala, Ayezel Munoz Gonzalez, Michael Wilkerson Tags: Letter to Editor Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Drugs & Pharmacology | Epilepsy | USA Health | Warnings